1. Home
  2. CGEM vs JBSS Comparison

CGEM vs JBSS Comparison

Compare CGEM & JBSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.18

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo John B. Sanfilippo & Son Inc.

JBSS

John B. Sanfilippo & Son Inc.

HOLD

Current Price

$74.51

Market Cap

913.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
JBSS
Founded
2016
1959
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
913.0M
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
CGEM
JBSS
Price
$16.18
$74.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
1
Target Price
$30.13
$109.00
AVG Volume (30 Days)
778.1K
90.9K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
3.26%
EPS Growth
N/A
N/A
EPS
N/A
4.55
Revenue
N/A
$1,107,246,000.00
Revenue This Year
N/A
$5.58
Revenue Next Year
$5.20
N/A
P/E Ratio
N/A
$16.75
Revenue Growth
N/A
3.79
52 Week Low
$5.68
$59.07
52 Week High
$16.74
$85.15

Technical Indicators

Market Signals
Indicator
CGEM
JBSS
Relative Strength Index (RSI) 65.46 36.37
Support Level $11.92 $74.24
Resistance Level N/A $84.04
Average True Range (ATR) 1.02 3.16
MACD 0.27 -0.59
Stochastic Oscillator 92.55 1.97

Price Performance

Historical Comparison
CGEM
JBSS

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About JBSS John B. Sanfilippo & Son Inc.

John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.

Share on Social Networks: